Jump to content
Wikipedia The Free Encyclopedia

TACT908

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Pharmaceutical compound
TACT908
Clinical data
Other namesTACT-908; Compound 28-12; 2ZEDMA; [2-(Indolizin-1-yl)ethyl]dimethylamine; Indolizine-DMT
Drug class Serotonin receptor agonist; Serotonin 5-HT1B receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
  • 2-indolizin-1-yl-N,N-dimethylethanamine
PubChem CID
Chemical and physical data
Formula C12H16N2
Molar mass 188.274g·mol−1
3D model (JSmol)
  • CN(C)CCC1=C2C=CC=CN2C=C1
  • InChI=1S/C12H16N2/c1-13(2)9-6-11-7-10-14-8-4-3-5-12(11)14/h3-5,7-8,10H,6,9H2,1-2H3
  • Key:CBZZXMYTGARRHB-UHFFFAOYSA-N

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches.[1] [2] [3] It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring.[1]

The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist.[1] [3] Its EC50 Tooltip half-maximal effective concentration at the serotonin 5-HT2A receptor is 52nM (Emax Tooltip maximal efficacy ≈ 30% of that of serotonin) and its EC50 at the serotonin 5-HT1B receptor is 143nM.[1] TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist.[1] [3] It showed little or no activity at 45other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs).[1] Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed.[1] The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) (IC50 Tooltip half-maximal inhibitory concentration = 7,252nM).[1]

TACT908 is under development by Tactogen.[1] [2] [3] It was patented by Matthew Baggott of Tactogen in 2023.[1] As of January 2025, the drug is in preclinical research for cluster headaches.[2] [3]

The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described.[1] It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-αMT).[1] 1ZP2MA was found to be a potent dopamine releasing agent, with an EC50 of 62nM.[1]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 WO patent 2023183613A2, Matthew J. Baggott, "Indolizine compounds for the treatment of mental disorders or inflammation", published 2023 September 28, assigned to Tactogen
  2. 1 2 3 Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. 1 2 3 4 5 "Tactogen Inc – Pipeline". Tactogen Inc. Tactogen. 8 February 2021. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT908. TARGETS: 5-HT1B, 5-HT2A ***. INDICATION: Cluster Headache. Prevalence: 0.24%. STATUS: Preclinical. [...] ***Partial agonist at 2A, non-hallucinogenic.

AltStyle によって変換されたページ (->オリジナル) /